Please ensure Javascript is enabled for purposes of website accessibility

Why Collegium Pharmaceutical Shares Are Sinking Today

By Keith Speights - Updated Feb 10, 2020 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors aren't happy about the drugmaker's proposed senior convertible note offering.

What happened

Shares of Collegium Pharmaceutical (COLL -2.86%) were sinking 13.6% as of 3:24 p.m. EST on Monday. The decline came after the drugmaker announced a $125 million proposed offering of senior convertible notes.

So what

The bad news with Collegium's proposed offering is that it means that dilution in the value of its existing shares is on the way. The notes that the company plans to offer allow holders to convert them to shares that Collegium will have to issue.

Businessman looking at red line going down with another declining chart in the background

Image source: Getty Images.

The good news with the drugmaker's move is that it will raise additional cash needed to help fund the purchase of the U.S. rights for Assertio Therapeutics' Nucynta franchise. Collegium announced on Feb. 6 that it had entered into an agreement with Assertio to buy the U.S. rights to its painkiller franchise for $375 million. 

Now what

Acquiring Nucynta should significantly boost Collegium's revenue. The company projects the franchise will rake in between $170 million and $180 million this year. That's more than the sales of between $150 million and $160 million that Collegium's own pain drug Xtampza ER is expecting in 2020.

Pharmaceutical stocks that rely on sales of opioid drugs, though, have proved to be highly volatile in light of the ongoing opioid epidemic in the U.S. Collegium is making a bet in buying Nucynta that these headwinds won't be too bad in the future.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Collegium Pharmaceutical, Inc. Stock Quote
Collegium Pharmaceutical, Inc.
$15.26 (-2.86%) $0.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.